| Anthony Blandin |
Anthony Blandin's current job(s) include Vice President-Quality & Compliance Management at Altimmune, Inc. and Member at Parenteral Drug Association. Formerly, Mr. Blandin held positions such as Executive Director-Manufacturing at Novavax, Inc. from 2001 to 2008, Senior Director-Quality Systems at Auxilium Pharmaceuticals LLC from 2012 to 2013, Senior Director-Technical Operations at Graceway Pharmaceuticals from 2008 to 2011, Vice President-Quality Assurance at Assertio Therapeutics, Inc. from 2020 to 2021, and Vice President-Quality Assurance at Zyla Life Sciences LLC from 2019 to 2020. Additionally, Mr. Blandin was a Member at American Society For Quality, Inc., a Partner at Sanofi SA, and a Member at International Society of Pharmaceutical Engineers Malaysia. Mr. Blandin's education history includes an undergraduate degree from Gwynedd-Mercy College. |
| Bertrand Georges |
Bertrand Georges is the founder of Altimmune UK Ltd., which was founded in 1992. He held the title of Chief Technical Officer from 2004 to 2015. Currently, Dr. Georges is the Chief Technology Officer at Altimmune, Inc. since 2015. In the past, he worked as the Head-Immunology at Sedac Therapeutics SA from 1999 to 2003. Dr. Georges obtained a doctorate degree from the Pasteur Institute of Iran. |
| M. Scott Harris |
M. Scott Harris was the founder of Lyric Pharmaceuticals, Inc. (founded in 2013) where he held the title of Chief Medical Officer from 2013 to 2018. He is currently working as a Principal at Middleburg Consultants, Inc., a Professor at Georgetown University School of Medicine, and the Chief Medical Officer at Altimmune, Inc. (since 2019). In his former positions, he served as the Chief Medical Officer & VP-Clinical Affairs at Napo Pharmaceuticals, Inc., Chief Medical Officer at Avaxia Biologics, Inc., Chief Medical Officer at OCERA Therapeutics LLC, and Chief Medical Officer at Tranzyme Pharma, Inc. (Canada). Dr. Harris obtained a doctorate degree from Harvard Medical School, an undergraduate degree from Harvard College, and a graduate degree from the University of Wisconsin School of Medicine & Public Health. |
| David J. Drutz |
David J. Drutz is the founder of Pacific Biopharma Associates, which was founded in 1999. He held the title of President at the company. Dr. Drutz currently holds the position of Director at Carolina Student Biotechnology Network. He is also an Independent Director at Altimmune, Inc. since 2017. Additionally, he is a Member of the American Society of Clinical Oncology, Inc., Alpha Omega Alpha Honor Medical Society, and the American Society for Clinical Investigation. Dr. Drutz has held several former positions, including President & Chief Executive Officer at Inspire Pharmaceuticals, Inc. from 1995 to 1998, President & Chief Executive Officer at Sennes Drug Innovations, Inc. from 1994 to 1995, and Chairman at Syntherica Corp. He was also Chairman at OCERA Therapeutics LLC in 2010, Executive Chairman & Chief Medical Officer at DARA BioSciences, Inc. from 2014 to 2015, Chairman at Tranzyme Pharma, Inc. (Canada) from 2000 to 2010, Lead Independent Director at Gentris Corp. from 2007 to 2014, and Director at Mirati Therapeutics, Inc. from 2000 to 2010. He has also served as a Director at Altimmune, Inc. and as a General Partner at Pacific Rim Ventures Co. Ltd. from 1999 to 2008. Furthermore, he held positions as an Assistant Professor at the University of California, San Francisco, a Professor at Texas University of Health Center at San Antonio, a VP-Biological Sciences & Clinical Investigation at Smithkline & French Laboratories US, Inc., and a Professor-Medicine at The University of Texas Health Science Center at Houston. He was also a Vice President-Clinical Development at DaIIchi Pharma Holdings, Inc.Dr. Drutz's education includes an undergraduate degree from the University of Louisville and a doctorate from the University of Louisville School of Medicine. |
| Richard I. Eisenstadt |
Richard I. Eisenstadt is currently the Chief Financial Officer & Director at Neostx, Inc. and the Chief Financial & Accounting Officer, Secretary at Altimmune, Inc. His former positions include Director-Strategic Planning & Development at Nimbus CD International, Inc., Finance Director at Cogent Neuroscience, Inc., Chief Financial Officer, Secretary & VP at OCERA Therapeutics LLC from 2003 to 2012, Chief Financial Officer & Secretary at Neos Therapeutics, Inc. from 2014 to 2021, Chief Financial Officer at ArborGen, Inc. from 2013 to 2014, Chief Financial Officer & Vice President-Finance at Tranzyme, Inc. from 2003 to 2012, Chief Financial Officer & Vice President-Finance at Tranzyme Pharma, Inc. (Canada) from 2003 to 2012, and Chief Financial Officer, Secretary & Treasurer at Aytu Biopharma, Inc. in 2021. He holds an MBA from James Madison University and an undergraduate degree from The University of North Carolina at Charlotte. |
| Mitchel B. Sayare |
Mitchel B. Sayare is currently the Chairman at Altimmune, Inc. He is also a Director at the Biotechnology Innovation Organization, Isabella Products, Inc., and Advanced Aesthetic Technologies, Inc. Previously, he served as a Director at ImmuCell Corp., ImmunoGen, Inc., Theraclone Sciences, Inc., CymoGen Dx LLC, Boston IVF LLC, PharmAthene, Inc., Xenogen Corp., and Apoptosis Technology, Inc. He also worked as an Assistant Professor of Biophysics & Biochemistry at the University of Connecticut. Dr. Sayare obtained his undergraduate degree from Ursinus College and his doctorate from Temple University School of Medicine. |
| Raymond M. Jordt |
Mr. Raymond M. Jordt is a Chief Business Officer at Altimmune, Inc. Mr. Jordt was previously employed as a Senior Associate by LV Management Group, LLC. He received his undergraduate degree from Arizona State University, a graduate degree from the University of Memphis and an MBA from Indiana University. |
| M. Scot Roberts |
Dr. M. S. Roberts is a Chief Scientific Officer at Altimmune, Inc. Dr. Roberts was previously employed as a Chief Scientific Officer by ImQuest BioSciences, Inc., a Director-Research & Development by Wellstat Biologics Corp., and a Chief Scientific Officer by Altimmune, Inc. /Old/. He received his graduate degree from Illinois State University and a doctorate degree from The Johns Hopkins University School of Medicine. |
| Vipin K. Garg |
Dr. Vipin K. Garg is a President, Chief Executive Officer & Director at Altimmune, Inc. and a Chief Executive Officer & Director at Neostx, Inc. He is on the Board of Directors at Altimmune, Inc. and Neostx, Inc. Dr. Garg was previously employed as a President, Chief Executive Officer & Director by Neos Therapeutics, Inc., a President, Chief Executive Officer & Director by OCERA Therapeutics LLC, a Chief Operating Officer by Apex Bioscience, Inc., a Vice President-Development by DNX Bio-Therapeutics, Inc, a Director-Marketing & Technical Services by Sumitomo Dainippon Pharma Co., Ltd., a Manager-Contract Services by Bio Response, Inc., a VP-Product Development & Manufacturing by DNX Corp., a Principal by Sumitomo Pharma America, Inc., and a President & Chief Executive Officer by Tranzyme Pharma, Inc. (Canada). He also served on the board at The North Carolina Biotechnology Center. He received his undergraduate degree from Chaudhary Charan Singh University, a graduate degree from Indian Agricultural Research Institute and a doctorate degree from the University of Adelaide. |
| Catherine Angell Sohn |
Dr. Catherine A. Sohn is an Independent Director at Altimmune, Inc., an Independent Director at Maze Therapeutics, Inc., a Non-Executive Chairman at BioEclipse Therapeutics, Inc., an Independent Director at Jazz Pharmaceuticals Plc and a Professor at University of the Sciences in Philadelphia. She is on the Board of Directors at Altimmune, Inc., Maze Therapeutics, Inc., Jazz Pharmaceuticals Plc, Dohmen Co., Jazz Pharmaceuticals, Inc., Ariel Pharmaceuticals, Inc., Eversana Life Science Services LLC and World Affairs Council of Philadelphia. Dr. Sohn was previously employed as an Independent Director by Axcella Health, Inc., an Independent Director by VL26, INC., an Independent Director by Neuralstem, Inc., an Independent Director by Landec Corp., a President by Sohn Health Strategies LLC, a Trustee by Licensing Executives Society USA & Canada, Inc., a Senior Vice President-Business Development by GlaxoSmithKline Consumer Healthcare LP, a VP-Worldwide Strategic Product Development by Smithkline Beecham Pharmaceuticals Ltd., a Senior Vice President by GlaxoSmithKline Plc, a Professor by Philadelphia College of Pharmacy, a Chairman by Eclipse Therapeutics, Inc., a Senior Vice President-Worldwide Business by GlaxoSmithKline LLC, and an Adjunct Professor by The University of California, San Francisco. She also served on the board at CHD Bioscience, Inc., Consumer Healthcare Products Association, Healthcare Businesswomens Association and World Self-Medication Industry Association. She received her doctorate degree from The University of California, San Francisco. |
| Klaus O. Schafer |
Dr. Klaus O. Schafer, MD, is an Independent Director at Altimmune, Inc. and a President & Chief Executive Officer at Touchstone Associates LLC. He is on the Board of Directors at Altimmune, Inc. Dr. Schafer was previously employed as a Chief Medical Officer & VP-Business Development by CACI International, Inc., a Vice President-Business Development by Compressus, Inc., a Chief Executive Officer by Tessarae LLC, and an Assistant Surgeon General-Science & Technology by US Air Force. He also served on the board at Altimmune, Inc. /Old/. He received his graduate degree from The University of Texas at Austin, a graduate degree from Eisenhower School and a doctorate degree from the University of Iowa. |
| Diane Kathryn Jorkasky |
Diane Kathryn Jorkasky is currently the Director at Alzheon, Inc., Independent Director at Altimmune, Inc., Director at Apie Therapeutics, Inc., and a Member of the Connecticut Academy of Science & Engineering. Previously, she held positions as Director at Tengion, Inc., Director at Q Therapeutics, Inc., Director at OSE Immunotherapeutics SA, Chief Development & Medical Officer, Senior VP at Aileron Therapeutics, Inc., Chief Medical Officer & SVP-Clinical Development at Endo Pharmaceuticals, Inc., Vice President-Clinical Research at Smithkline Beecham Holdings Corp., VP-Worldwide Clinical Research Operations at Pfizer (St. Louis), Chief-Nephrology at Penn Presbyterian Medical Center, and Chief Medical Officer, EVP & Head-Development at Complexa, Inc. Dr. Jorkasky obtained a doctorate degree from the University of Pennsylvania Medical Center in 1977 and an undergraduate degree from The College of Wooster. |
| Wayne F. Pisano |
Mr. Wayne F. Pisano is an Independent Director at Altimmune, Inc., a Chairman at Oncolytics Biotech, Inc. and a President at Pirus Biological & Vaccine Consulting. He is on the Board of Directors at Altimmune, Inc., River Acquisition Corp. and Chattem, Inc. Mr. Pisano was previously employed as a Chairman by Provention Bio, Inc., a President, Chief Executive Officer & Director by VaxInnate Corp., an Independent Director by IMV, Inc., a President & Chief Executive Officer by Sanofi Pasteur, a Vice President by Novartis Pharmaceuticals Corp., and a Senior Vice President-Vaccines by Sanofi-Aventis SA. He also served on the board at Aeras Global TB Vaccine Foundation. He received his undergraduate degree from St. John Fisher College and an MBA from the University of Dayton. |
| Philip L. Hodges |
Mr. Philip L. Hodges is an Independent Director at Altimmune, Inc., a Founder & Managing Partner at Redmont Venture Partners, Inc. and a Managing Partner at Redmont Capital. He is on the Board of Directors at Altimmune, Inc., American Legal Search LLC, Birmingham Venture Club, Inc., Impact Alabama and Reliant Medical Products, Inc. Mr. Hodges was previously employed as a Principal by Atherotech, Inc. and a Principal by Encompass Health Corp. He also served on the board at Altimmune, Inc. /Old/. He received his undergraduate degree from Brock School of Business. |
| John M. Gill |
John M. Gill founded TetraLogic Pharmaceuticals Corp. in 2001, where he worked as Director from 2013 to 2014. Dr. Gill also currently works at Millennium Information Technologies Ltd., as Chief Executive Officer from 2013, Altimmune, Inc., as Independent Director from 2004, and Torstone Technology Ltd., as Chief Operating Officer. Dr. Gill also formerly worked at PharmAthene, Inc., as President, Chief Executive Officer & Director from 2015 to 2017, 3-Dimensional Pharmaceuticals, Inc., as Chief Financial Officer, Director & Executive VP, PharmAthene, Inc., as Director in 2007, Theraclone Sciences, Inc., as Director, The Biotechnology Greenhouse Corp. of Southeastern PA, as Director, Ben Franklin Technology Partners, as Director, FIS Capital Markets US LLC (Pennsylvania), as SVP-Corporate Development & Strategy, GSK Equity Investments Ltd., as President, US Department of Defense (District of Columbia), as Principal from 1971 to 1973, Smithkline & French Laboratories US, Inc., as Chief Operating Officer, SunGard Financial Systems, as President-Global Technology, Nova Pharmaceutical Corp., as Chief Operating Officer, GlaxoSmithKline LLC, as VP-Research & Development Operations, and Sungard Global Services France SA, as President in 2011. Dr. Gill received his undergraduate degree in 1975 from Rutgers State University of New Jersey, graduate degree from Yale University, and undergraduate degree from the University of British Columbia. |
